Macupatide
| Clinical data | |
|---|---|
| Other names | LY3532226 |
| Drug class | Gastric inhibitory polypeptide receptor agonist |
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C232H357N49O72 |
| Molar mass | 4984.679 g·mol−1 |
Macupatide (LY3532226) is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist under development for diabetes and obesity.[1]
References
- ↑ Roell, William; Alsina-Fernandez, Jorge; Qu, Hongchang; Coskun, Tamer; Benson, Charles; Haupt, Axel; Kelly, Ronan P.; O'Farrell, Libbey; Sloop, Kyle W.; Steele, James P.; Ficorilli, James; Regmi, Ajit; Rettiganti, Mallikarjuna; Urva, Shweta; Mather, Kieren J.; Pratt, Edward (January 2026). "Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies". Molecular Metabolism. 103 102298. doi:10.1016/j.molmet.2025.102298. ISSN 2212-8778. PMC 12808604. PMID 41391569.